Clinical Trials Logo

Filter by:
NCT ID: NCT05182697 Not yet recruiting - Clinical trials for Autism Spectrum Disorder (ASD)

SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Start date: September 2023
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)

NCT ID: NCT05126888 Not yet recruiting - Tourette Syndrome Clinical Trials

SCI-110 in the Treatment of Tourette Syndrome

Start date: February 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.

NCT ID: NCT05106218 Not yet recruiting - Laparoscopy Clinical Trials

Assessment of the SurroundScope in Urologic Surgical Procedures

Start date: March 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate standard urological surgeries using the 270Surgical system vs same procedures using the standard scope

NCT ID: NCT05065346 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC

Start date: March 2025
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device (DaRT) as a treatment prior to additional radiation or chemo therapy.

NCT ID: NCT05054465 Not yet recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL

ITALLI001
Start date: October 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a national, multicenter, phase II clinical trial to evaluate the potential benefit of pre-transplant consolidation and post-transplant maintenance with navitoclax and venetoclax in patients with T-ALL, LBL and MPAL T/M in first complete remission designated for allogeneic transplantation. Pre-transplantation consolidation with venetoclax and navitoclax: Patients in CR designated for transplantation will be treated with venetoclax 400 mg QD and navitoclax 50mg QD according to the RP2D presented by Pullarkat et al. (Cancer Discov . 2021 Feb 16;candisc.1465.2020. doi: 10.1158/2159-8290.CD-20-1465.) for two 28 day cycles. Following 2 cycles re-staging marrow including MRD assessment and imaging as need will be followed by alloSCT according to local protocol. Post-transplantation maintenance with venetoclax and navitoclax: Within 90 days from alloSCT patients will be started on venetoclax and navitoclax maintenance. Due to lack of data regarding the toxicity of navitoclax and venetoclax in the ALL post alloSCT maintenance setting a dose escalation scheme based on the BOIN design will be applied as outlined (TBD) with a maximal dose of venetoclax 400 mg QD and navitoclax 50mg QD according to the RP2D presented by Pullarkat et al. (Cancer Discov . 2021 Feb 16;candisc.1465.2020. doi: 10.1158/2159-8290.CD-20-1465).

NCT ID: NCT05013151 Not yet recruiting - Clinical trials for Effect of Dates and Castor Oil on Spontaneous Labor

The Effect of Dates and Castor Oil on the Initiation of Spontaneous Labor in Primigravida Parturients

Start date: August 24, 2021
Phase: N/A
Study type: Interventional

Finding a natural and efficient method to improve the chance of entering spontaneous labor beyond 39 weeks of gestation will address both the medical necessity and the will of many parturients to avoid medical interventions. In this study we aim to evaluate the effect of dates and castor oil on the initiation of spontaneous labor in primigravida parturients.

NCT ID: NCT04937426 Not yet recruiting - Helicobacter Pylori Clinical Trials

Development of a Laboratory Test for the Detection of a Fluorescent-labeled Urease Inhibitor Marker Attached to Helicobacter Pylori

Start date: July 2021
Phase: N/A
Study type: Interventional

The aim of this study is to compare the usual rapid urease test (RUT) to a new florescent-labeled urease inhibitor marker to diagnose Helicobacter Pylori.

NCT ID: NCT04899466 Not yet recruiting - Dehiscence Wound Clinical Trials

Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

This is a prospective, single arm study, consisting of 20 women with abdominal surgical wound dehiscence that requires secondary closure. The participants will receive a weekly application of ActiGraft for 4 weeks, or until complete healing of the wound (the earlier of the two). An historic matched-control group of 20 patients will be compared retrospectively

NCT ID: NCT04833530 Not yet recruiting - Ultrasonography Clinical Trials

The Effect of Preoperative Anxiety, on Gastric Antrum Size in Women Undergoing in Vitro Fertilization

Start date: April 1, 2021
Phase:
Study type: Observational

Pulmonary aspiration is one of the most serious risks of general anesthesia and has been reported to occur in as many as 1 in 4000 cases of general anesthesia. Gastric ultrasound is an emerging point-of-care tool that provides bedside information on gastric content and volume. There have been a few factors which are thought to increase gastric size. Delayed gastric emptying such as caused by gastroparesis in Diabetes Mellitus is an example. Certain surgeries also cause gastroparesis. Other preoperative factors including pain, preoperative anxiety, and blood levels of estradiol or progesterone are less well studied.

NCT ID: NCT04823364 Not yet recruiting - Clinical trials for Attention Deficit Disorder With Hyperactivity

Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment

ADHD
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Background: Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neurobiological brain disorders. Diagnosis of ADHD in adults is complex and subjective. Recent studies give further support for the involvement of glutamatergic and GABAergic neurotransmitters in the pathophysiology of ADHD. Studies show that glutamate (Glu) and GABA change according to stimulant treatment. Measuring modulations in the anterior cingulate cortex (ACC) of Glu and GABA may help to explore the pathophysiology of ADHD and give a diagnostic biomarker tool for ADHD in adults. Aim: To characterize Glu and GABA levels in the ACC, by using the proton Magnetic Resonance Spectroscopy ([1H]MRS) system in adults with ADHD compared to healthy control subjects (HCS), before and after stimulant treatment, and to correlate between Glu and GABA levels and clinical symptoms. Method: ADHD adults ages 18-40 years (N= 35), and HCS (N= 25), will fill out a DSMV and ASRS questionnaire. Spectroscopic analyses will be done using 1H MRS (3T) in ADHD adults, before and after stimulant treatment (Methylphenidate /Mixed Amphetamine salts) in an open-label fashion as compared to HCS. Proton spectra will be acquired from the ACC.